Literature DB >> 10582897

Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

H Tomioka1, K Sato, T Akaki, H Kajitani, S Kawahara, M Sakatani.   

Abstract

We compared the in vitro antimycobacterial activity of a new fluoroquinolone, HSR-903, with strong activity against gram-positive cocci with those of levofloxacin (LVFX), sitafloxacin (STFX), and gatifloxacin (GFLX). The MICs of the quinolones for Mycobacterium tuberculosis and Mycobacterium avium complex were in the order STFX approximately GFLX < LVFX <== HSR-903 and STFX <== GFLX <== HSR-903 <== LVFX, respectively. HSR-903 effectively eliminated intramacrophagial M. tuberculosis, as did LVFX, and exhibited bacteriostatic effects against M. tuberculosis replicating in type II alveolar cells.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10582897      PMCID： PMC89602          DOI： 10.1128/AAC.43.12.3001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.

Authors:  K Sato; H Tomioka
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

2.  New drugs for tuberculosis.

Authors:  C Grassi
Journal:  Expert Opin Investig Drugs       Date:  1997-09       Impact factor: 6.206

3.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Levofloxacin in the treatment of drug-resistant tuberculosis.

Authors:  W W Yew; K F Au; J Lee; C H Chau
Journal:  Int J Tuberc Lung Dis       Date:  1997-02       Impact factor: 2.373

Review 5.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

6.  In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

Authors:  S E Hoffner; L Gezelius; B Olsson-Liljequist
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

7.  In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.

Authors:  A Watanabe; Y Tokue; H Takahashi; T Kikuchi; T Kobayashi; K Gomi; S Fujimura; T Nukiwa
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 8.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

9.  In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

Authors:  H Saito; H Tomioka; K Sato; S Dekio
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Mycobacterium tuberculosis invades and replicates within type II alveolar cells.

Authors:  L E Bermudez; J Goodman
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441
View more
  8 in total

1.  Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; H Kajitani; T Akaki; S Shishido
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand.

Authors:  Manoon Leechawengwongs; Therdsak Prammananan; Sarinya Jaitrong; Pamaree Billamas; Nampueng Makhao; Nongnard Thamnongdee; Arirat Thanormchat; Arisa Phurattanakornkul; Somcharn Rattanarangsee; Chate Ratanajaraya; Areeya Disratthakit; Angkana Chaiprasert
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 4.  The role of fluoroquinolones in tuberculosis today.

Authors:  S E Berning
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.

Authors:  Martin Bråbäck; Kristian Riesbeck; Arne Forsgren
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.

Authors:  Go-Eun Choi; Ki-Nam Min; Choul-Jae Won; Kyeongman Jeon; Sung Jae Shin; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

7.  Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity.

Authors:  Siyuan He; Qi Guo; Lan Zhao; Liyun Xu; Junsheng Fan; Wenye Wu; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

8.  Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.

Authors:  Keiji Fujiwara; Fumiko Uesugi; Koji Furuuchi; Yoshiaki Tanaka; Takashi Yoshiyama; Mikio Saotome; Ken Ohta; Satoshi Mitarai; Kozo Morimoto
Journal:  Microbiol Spectr       Date:  2021-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.